Drug
KPT-330
KPT-330 is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
33%(1 trials)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
active_not_recruiting125%
completed375%
Recent Activity
1 active trials
Showing 4 of 4
active_not_recruitingphase_1
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT02091245
completedphase_1
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT01607892
completedphase_1
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02471911
completedphase_1
Phase I Study of KPT330 in Asian Patients
NCT02078349
Clinical Trials (4)
Showing 4 of 4 trials
NCT02091245Phase 1
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
NCT01607892Phase 1
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
NCT02471911Phase 1
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
NCT02078349Phase 1
Phase I Study of KPT330 in Asian Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4